BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/31/2024 10:42:49 AM | Browse: 199 | Download: 740
 |
Received |
|
2024-08-20 01:10 |
|
Peer-Review Started |
|
2024-07-26 03:25 |
|
First Decision by Editorial Office Director |
|
2024-09-15 20:47 |
|
Return for Revision |
|
2024-09-15 20:47 |
|
Revised |
|
2024-09-29 04:22 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-10-18 01:22 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-10-18 06:00 |
|
Articles in Press |
|
2024-10-18 06:00 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-10-28 01:25 |
|
Publish the Manuscript Online |
|
2024-10-31 10:42 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Letter to the Editor |
| Article Title |
Elafibranor alleviates alcohol-related liver fibrosis by restoring intestinal barrier function
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yu-Qi Sun, Yang Wu, Meng-Ran Li, Yu-Yao Wei, Mei Guo and Zi-Li Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
No. 82474164, No. 82305046, No. 82000572 |
| Major Project of the Natural Science Research of Jiangsu Higher Education Institutions |
No. 22KJB310013 |
| Science and Technology Project of Jiangsu Province |
No. BK20200840 |
| Natural Science Foundation of Jiangsu Province |
No. BK20220467 |
|
| Corresponding Author |
Zi-Li Zhang, MD, PhD, Professor, Jiangsu Key Laboratory for Pharmacology and Safety Evaluation of Chinese Materia Medica, Nanjing University of Chinese Medicine, No. 138 Xianlin Avenue, Nanjing 210023, Jiangsu Province, China. zilizhang@njucm.edu.cn |
| Key Words |
Liver fibrosis; Ethanol; Gut barrier function; Apoptosis; Autophagy; Peroxisome proliferator-activated receptor |
| Core Tip |
Peroxisome proliferator-activated receptor (PPAR) can inhibit the pathological process of alcohol-related liver disease (ALD). However, the dual PPARα/δ agonist elafibranor has been studied mainly in metabolic dysfunction-associated steatohepatitis and primary cholangitis, and its role in ALD and its mechanism need to be further explored. |
| Publish Date |
2024-10-31 10:42 |
| Citation |
Sun YQ, Wu Y, Li MR, Wei YY, Guo M, Zhang ZL. Elafibranor alleviates alcohol-related liver fibrosis by restoring intestinal barrier function. World J Gastroenterol 2024; 30(43): 4660-4668 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i43/4660.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i43.4660 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
